Everest Medicines Set to Showcase Innovations at J.P. Morgan Healthcare Conference Everest Medicines is preparing to present key updates at the upcoming J.P. Morgan Healthcare Conference in San Francisco, highlighting its focus on innovative therapies.

Everest Medicines Set to Showcase Innovations at J.P. Morgan Healthcare Conference #China #Shanghai #J.P._Morgan #Biopharmaceutical #Everest_Medicines

Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy Everest Medicines announced its interim results for the first half of 2025, revealing a significant 48% growth year-over-year driven by its innovative dual-engine strategy and key product advancements.

Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy #China #Shanghai #Everest_Medicines #NEFECON #VELSIPITY

Everest Medicines Set to Present at Major Investor Conferences in September Everest Medicines is participating in key investor conferences in September 2025. Join President Ian Woo in New York City for insights.

Everest Medicines Set to Present at Major Investor Conferences in September #China #New_York_City #biopharmaceuticals #Everest_Medicines #Hong_Kong_Stock_Exchange

Everest Medicines Makes Strategic Move by Investing $30.9 Million in I-MAB Everest Medicines announces a strategic investment of approximately $30.9 million in I-MAB, enhancing its oncology capabilities and global presence.

Everest Medicines Makes Strategic Move by Investing $30.9 Million in I-MAB #China #Shanghai #Investment #Everest_Medicines #I-Mab

Everest Medicines Unveils Encouraging Phase 1b/2a Clinical Trial Outcomes of BTK Inhibitor EVER001 at European Renal Congress Everest Medicines presented promising outcomes from its Phase 1b/2a trial of EVER001, a novel BTK inhibitor targeting primary membranous nephropathy, at the European Renal Congress.

Everest Medicines Unveils Encouraging Phase 1b/2a Clinical Trial Outcomes of BTK Inhibitor EVER001 at European Renal Congress #China #Shanghai #EVER001 #Everest_Medicines #primary_membranous_nephropathy

Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year Everest Medicines has unveiled its financial results for the 2024 fiscal year, showcasing a major revenue increase of 461% and a successful launch of NEFECON in China.

Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year #China #Shanghai #Everest_Medicines #NEFECON #XERAVA

Everest Medicines Marks a Milestone with First Patient Dosed for EVM16 Personalized mRNA Cancer Vaccine Everest Medicines has taken a significant step in cancer treatment with the first patient receiving EVM16, a personalized mRNA vaccine, at Peking University Cancer Hospital.

Everest Medicines Marks a Milestone with First Patient Dosed for EVM16 Personalized mRNA Cancer Vaccine #China #Beijing #Everest_Medicines #mRNA_Vaccine #EVM16

Everest Medicines Reveals Promising Outcomes from Phase 1b/2a Trial of EVER001 for Primary Membranous Nephropathy Everest Medicines presents encouraging results from a Phase 1b/2a clinical trial of EVER001, a BTK inhibitor targeting primary membranous nephropathy that shows promising effectiveness and safety.

Everest Medicines Reveals Promising Outcomes from Phase 1b/2a Trial of EVER001 for Primary Membranous Nephropathy #China #Shanghai #Clinical_Trial #EVER001 #Everest_Medicines

Exciting Progress for Everest Medicines with Phase 1b/2a Trial of EVER001 Showing Promising Results Everest Medicines reports positive preliminary results from the Phase 1b/2a trial of EVER001, a new BTK inhibitor aimed at treating primary membranous nephropathy, showing significant clinical remission rates among participants.

Exciting Progress for Everest Medicines with Phase 1b/2a Trial of EVER001 Showing Promising Results #EVER001 #BTK_Inhibitor #Everest_Medicines #